NO20052814L - Cytomodulerende peptider for behandling av interstitielle cystitt - Google Patents

Cytomodulerende peptider for behandling av interstitielle cystitt

Info

Publication number
NO20052814L
NO20052814L NO20052814A NO20052814A NO20052814L NO 20052814 L NO20052814 L NO 20052814L NO 20052814 A NO20052814 A NO 20052814A NO 20052814 A NO20052814 A NO 20052814A NO 20052814 L NO20052814 L NO 20052814L
Authority
NO
Norway
Prior art keywords
treatment
interstitial cystitis
cytomodulatory
peptides
modulation
Prior art date
Application number
NO20052814A
Other languages
English (en)
Other versions
NO20052814D0 (no
Inventor
Alexis E Te
Timothy Fong
Original Assignee
Sangstat Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangstat Medical Corp filed Critical Sangstat Medical Corp
Publication of NO20052814D0 publication Critical patent/NO20052814D0/no
Publication of NO20052814L publication Critical patent/NO20052814L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Sammendrag Fremgangsmåtene og sammensetningene angår behandling av urinblæreforstyrrelser. Fremgangsmåtene tilveiebringer behandling spesielt for interstitiell cystitt og relaterte forstyrrelser. Fremgangsmåtene omfatter videre behandling for å påvirke forskjellige manifestasjoner assosiert med interstitiell cystitt, inkludert redusert histaminfrigivelse, modulering av substans-P-ekspresjon, modulering av nervevekstfaktorekspresjon, modulere nivåer av forskjellige cytokiner, og opprettholde urin/blod-barrierens integritet.
NO20052814A 2002-11-15 2005-06-10 Cytomodulerende peptider for behandling av interstitielle cystitt NO20052814L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42668402P 2002-11-15 2002-11-15
US47083903P 2003-05-15 2003-05-15
PCT/US2003/037043 WO2004045554A2 (en) 2002-11-15 2003-11-17 Cytomodulating peptides for treating interstitial cystitis

Publications (2)

Publication Number Publication Date
NO20052814D0 NO20052814D0 (no) 2005-06-10
NO20052814L true NO20052814L (no) 2005-08-04

Family

ID=32329122

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052814A NO20052814L (no) 2002-11-15 2005-06-10 Cytomodulerende peptider for behandling av interstitielle cystitt

Country Status (13)

Country Link
US (1) US7671026B2 (no)
EP (1) EP1594519A4 (no)
JP (1) JP2006516546A (no)
KR (1) KR20050086676A (no)
AU (1) AU2003294357A1 (no)
BR (1) BR0316290A (no)
CA (1) CA2505922A1 (no)
CO (1) CO5640064A2 (no)
MA (1) MA27607A1 (no)
MX (1) MXPA05005101A (no)
NO (1) NO20052814L (no)
RU (1) RU2005118425A (no)
WO (1) WO2004045554A2 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008014484A1 (en) * 2006-07-27 2008-01-31 University Of Maryland, Baltimore Cellular receptor for antiproliferative factor
CN102089320B (zh) * 2008-01-24 2015-11-25 埃斯佩兰斯医药公司 溶解结构域融合构建体及其制备和使用方法
AU2009282625A1 (en) * 2008-08-18 2010-02-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Derivatives of APF and methods of use
JP5857056B2 (ja) 2010-10-14 2016-02-10 ザイジェン インフラメーション エルティーディー 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
CA2915960A1 (en) 2013-06-17 2014-12-24 Asana Biosciences, Llc 5t4-targeted immunofusion molecule and methods
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2014206426A1 (en) * 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
CA2947508A1 (en) * 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
US10859579B2 (en) * 2016-03-31 2020-12-08 William Beaumont Hospital Methods for detecting, diagnosing and treating ulcerative interstitial cystitis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696545B1 (en) * 1997-04-11 2004-02-24 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
AU761717B2 (en) * 1997-04-11 2003-06-05 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
AU3568499A (en) * 1998-04-17 1999-11-08 University Of Maryland At Baltimore Method of treating interstitial cystitis with recombinant heparin-binding epidermal growth factor-like growth factor (hb-egf)
MXPA05003063A (es) * 2002-09-20 2005-05-27 Alcon Inc Uso de inhibidores de la sintesis de citosina para el tratamiento de trastornos de ojos secos.

Also Published As

Publication number Publication date
CO5640064A2 (es) 2006-05-31
EP1594519A4 (en) 2006-08-16
MXPA05005101A (es) 2005-09-08
EP1594519A2 (en) 2005-11-16
RU2005118425A (ru) 2006-02-10
KR20050086676A (ko) 2005-08-30
JP2006516546A (ja) 2006-07-06
CA2505922A1 (en) 2004-06-03
BR0316290A (pt) 2005-10-11
AU2003294357A1 (en) 2004-06-15
US20060194738A1 (en) 2006-08-31
WO2004045554A3 (en) 2005-07-07
NO20052814D0 (no) 2005-06-10
US7671026B2 (en) 2010-03-02
WO2004045554A2 (en) 2004-06-03
MA27607A1 (fr) 2005-11-01

Similar Documents

Publication Publication Date Title
NO20052814L (no) Cytomodulerende peptider for behandling av interstitielle cystitt
MY151032A (en) Treatment of tnf? related disorders
NO20045043L (no) Pyrimidinonforbindelser, sammensetninger og fremgangsmater
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
NO20053041L (no) Behandling av diabetes.
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
CY1105080T1 (el) Ενωσεις θειενοπυρρολυλιου και φουρανοπυρρολυλιου και η χρηση τους ως συνδετες η4 υποδοχεα ισταμινης
ATE322258T1 (de) Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
WO2003103575A3 (en) COMPOUNDS, COMPOSITIONS AND METHODS
SG149027A1 (en) Substituted urea derivatives for treating cardiac diseases
MXPA04001187A (es) Receptores de interleucina-1 en el tratamiento de enfermedades.
MXPA06000933A (es) Compuestos de aminopirazol y uso como inhibidores de chk1.
WO2005099715A3 (en) Treatment of ophthalmic conditions with mineralcorticoids
NO20055832L (no) Fremstilling og anvendelse av arylalkylsyrederivater for behandling av fedme
WO2006047716A3 (en) Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus associated disease
EA200700262A1 (ru) Арилидены для лечения заболеваний, опосредуемых эстроген-родственным рецепторам альфа
NO20065079L (no) Materialer og metoder for behandling av koaguleringssykdommer
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
NO20052267L (no) Forbindelser, Preparater og Metoder
MY140169A (en) Compounds, compositions, and methods
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz